| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion due to NICE appraisal TA278: Omalizumab for treating severe persistent allergic asthma (replaced TA133) |
|
Medicine details |
|
| Medicine name | omalizumab (Xolair®) |
| Formulation | powder and solvent for solution for injection |
| Reference number | 229 |
| Indication | Add-on therapy to improve asthma control in adult and adolescent patients (12 years of age and above) with severe, persistent, allergic asthma |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 29/11/2006 |
| NICE guidance | TA278: Omalizumab for treating severe persistent allergic asthma (replaced TA133) |